На главную
Результаты поиска “Prostate cancer metastatic diagnostic company”
Apalutamide Delays Prostate Cancer Metastasis By Over 2 Years
 
06:10
Apalutamide Delays Prostate Cancer Metastasis By Over 2 Years A newly developed drug called apalutamide can delay the progression of a hard-to-treat form of prostate cancer, research shows. The drug, an investigational androgen receptor inhibitor, was the focus of a multi-institutional, phase 3 clinical trial led by investigators from Massachusetts General Hospital (MGH) and University of California, San Francisco (UCSF). “Our study found that apalutamide treatment markedly improved metastasis-free survival and other clinical outcomes in men with castration-resistant prostate cancers and no detectable metastases. At this time, there are no approved treatments for men in that situation, so we need to wait until their disease progresses to add the standard therapies that have been approved for metastatic disease,” corresponding author Matthew Smith, MD, PhD, of the MGH Cancer Center, said. Androgen-deprivation Therapy Androgen-deprivation therapy, either through the use of drugs that suppress testosterone production, or surgical removal of the testicles, is standard treatment for men with metastatic prostate cancer and is also used for non-metastatic cancer. Unfortunately, androgen deprivation stops working for almost all patients, leading to what is called castration-resistant disease. In such patients whose cancer has not yet spread, a rapid rise in prostate-specific antigen (PSA) levels warns of the near-term development of metastases, the major cause of complications and death from prostate cancer. Prostate cancer is the second most deadly form of the disease for men in the US, and the American Cancer Society anticipates that it will kill nearly 30,000 people this year alone while another 164,000 are diagnosed. Most forms of prostate cancer grow slowly, meaning they may not be detectable for many years. Apalutamide Apalutamide works by binding to the androgen receptor, blocking its activation by testosterone and other androgens. Apalutamide is being developed by The Janssen Pharmaceutical Companies of Johnson & Johnson, which sponsored this study. A previous phase 2 clinical trial of apalutamide for men with nonmetastatic, castration-resistant prostate cancer at high risk of progression showed that the drug was well tolerated and achieved responses in most patients. Apalutamide is similar to enzalutamide both structurally and pharmacologically . Enzalutamide was approved by the Food and Drug Administration for medical use in the United States in August 2012. This trial, conducted at 322 sites in 26 countries in North American, Europe and the Asia-Pacific, involved more than 1,200 patients between October 2013 and December 2016. All participants had nonmetastatic prostate cancer that had stopped responding to androgen-deprivation therapy and a rapid PSA doubling time, indicating an elevated risk for metastasis. Participants were randomized to receive a daily oral dose of either apalutamide or a placebo and were evaluated every 16 weeks for signs of disease progression. As of May 19, 2017, the average progression-free survival – the time from randomization to the first evidence of metastasis – was 40.5 months for participants receiving apalutamide, compared with 16.2 months for those taking a placebo. Taking apalutamide also reduced other signs of disease progression – including development of imaging-confirmed metastasis or symptoms such as bone pain – and death from any cause. Members of the apalutamide group who continued to benefit from the drug were able to continue treatment, and members of the placebo group could begin receiving apalutamide on an open-label basis. Several additional phase 3 trials of apalutamide are currently underway for other prostate cancer disease states, including studies of both earlier and later stage disease. The current report was co-authored by 16 additional investigators – from academic medical centers and from Janssen Research & Development – in nine countries. “This trial’s results suggest that the availability of apalutamide should offer men with nonmetastatic, castration-resistant prostate cancer a treatment that can delay or prevent the development of metastases and other complications associated with disease progression,” Semifinals, Australian Open 2018, Australian Open, 2018 Australian Open, vaccine, nydailynews, injection, Cancer, Immunotherapy, American Heart Association, amyloid beta, united Arab emirates, oseltamivir, Georgia health officials, flu-related deaths, health, Killer, flu, flu season, flu virus, virus, spokesman, timesfreepress, fox10phoenix, heart health, CNN Live, CNN News, CNN TV TIme, CNN TV, FOX, FOX TV Live, FOx TV, FOX TIme News, FOx NEws TIme, Fox News, https://www.youtube.com/playlist?list=PL8c-enNLOhBmoqNIUpY1QMQszVfc3yLT-
Просмотров: 255 Tey Yomiko
Abiraterone Delays Metastatic Prostate Cancer Growth
 
01:16
A new study suggests that adding abiraterone acetate plus prednisone to standard hormonal therapy lowers the chance of death by 38%. Read the full story here ➨http://bit.ly/metastatic-cancer-asco --------------------------------------------------------------- Subscribe to DoveMed’s channel to learn about more medical studies taking place! --------------------------------------------------------------- Produced by Stephen Umunna Written by Krish Tangella MD, FCAP and Stephen Umunna --------------------------------------------------------------- Connect with DoveMed Online ➨Visit DoveMed.com: http://bit.ly/dovemed ➨Find DoveMed on Facebook: http://bit.ly/dovemed-facebook ➨Follow DoveMed on Twitter: http://bit.ly/dovemed-twitter ➨Follow DoveMed on Instagram: http://bit.ly/dovemed-instagram ➨Follow DoveMed on LinkedIn: http://bit.ly/dovemed-linkedin ➨Follow DoveMed on Pinterest: http://bit.ly/dovemed-pinterest --------------------------------------------------------------- DoveMed is a trusted, physician-approved, and simple to understand health technology portal geared to help consumers make better decisions regarding all-around health and well-being – their own as well as their loved ones. Our company is independent and is not owned by any pharmaceutical, medical, or media companies.
Просмотров: 103 DoveMed
Nanoknife IRE – A new method for treating prostate cancer
 
04:02
https://vitusprostate.com Michael Stehling talks about preservation of continence and potency in men with prostate cancer with NanoKnife/ Irreversible Electroporation (IRE). He explains how the technology works and what the advantages are. Prof. Stehling talks in detail about the prostate and how it is surrounded by delicate structures that are important for urinary and erectile functions in men. Established treatment options such as prostatectomy impair these functions. With the NanoKnife system, it is possible to preserve vital structures around the prostate and minimize side effects. Prof. Stehling and his team have treated over 650 prostate cancer patients with IRE, and can report an impotence rate of less than 10% and an incontinence rate of 0%. With specialist prostate cancer treatment clinics in Germany, Austria, Switzerland, and now in the USA, Vitus are the world leaders in prostate cancer treatment, offering patients hope, innovative treatment and impressive results. Vitus Prostate Center San Diego opened in 2017, inspired by the success of The Prostate Center, founded by Professor Michael K. Stehling in Offenbach am Main in Germany, in 2010. Professor Stehling’s inspiration for the Centers came from the realization that a paradigm shift was needed in the treatment of prostate cancer: away from traditional methods that were imprecise, and towards a new targeted, gentle procedure that would reduce side effects, such as impotence and incontinence. The best expression of this paradigm shift is focal therapy with the NanoKnife, the most up-to-date treatment for prostate cancer, and one in which we are the world’s leading experts. ► Visit out website to learn more about Irreversible Electroporation for the treatment of prostate cancer: https://vitusprostate.com ► Want to know in detail how IRE works? We have an extended science page that explains it all: https://vitusprostate.com/science/ ► Connect to us via Facebook:https://www.facebook.com/VITUS-Prostate-Center-San-Diego-449580308770767/ ► Reach our team via LinkedIn: https://www.linkedin.com/company/18343389/ Sie sprechen Deutsch? Auf unserer YouTube-Seite gibt es eine Playlist mit Videos in deutscher Sprache: https://www.youtube.com/watch?v=-7KhVNvsat0&list=PLZ8e4dTKsT7yLq4VlAfNevqF11E29BUbu
Просмотров: 4572 Vitus Prostate Center
Spreading Prostate Cancer - Dr. Joel Wallach
 
13:49
http://www.wallachslog.com Call: +1 (800) 212-2613 Outside USA +1 (774) 322-1690 LÍNEA ESPAÑOLA +1 (910) 241-0314 Dr. Joel Wallach's Books: http://www.drwallachsbooks.com Dr. Joel Wallach’s Products : http://drwallachyoungevity.com Dr. Joel Wallach’s Daily Radio Program : https://www.wallachslog.com/dead-doctors-don-t-lie-radio-show-.html Compre los productos del Dr. Wallach : http://www.ygyespanol.com Australia: http://youngevityaustralia.com Europe: http://youngevityeurope.com New Zealand: http://youngevitynz.co.nz Dr. Joel Wallach takes a call from Michael who has been diagnosed with prostate cancer that has moved into his bones. Dr. Joel Wallach Recommends: Healthy Body Brain and Heart Pak™ - Original http://bit.ly/2o7aTlU Ultimate Prost Fx™ - 60 capsules http://bit.ly/2lLtvaa XeraTest™ Hormonal Support for Men http://bit.ly/2ykXs9Y ZRadical™ - 32 fl oz http://bit.ly/2yVpwkL Ultimate Selenium™ - 90 capsules http://bit.ly/2IHYuSA Slender Fx™ Sweet Eze™ - 120 capsules http://bit.ly/2s6GFBg I26 31 Day Supply - Canister http://bit.ly/2lHNZ3y Comprehensive Joint Care : http://www.projointfx.com Supreme Cardio Support : http://procardiofx.com Give your body the nutritional support it needs to help improve cardiovascular endurance and performance with CardioBeets! Order Here: http://bit.ly/2uSUtP3 Dr. Joel Wallach Recommends Getting the Trilogy of Books: Let's Play Doctor ....http://amzn.to/2egFyKR Let's Play Herbal Doctor .... http://amzn.to/2dEcxqf Passport to Aromatherapy... http://amzn.to/2doJsxa Also Dead Doctors Don't Lie….http://amzn.to/2d124af Epigenetics: The Death of the Genetic Theory of Disease Transmission…http://amzn.to/2d110mZ Hell's Kitchen: Causes, Prevention and Cure of Obesity, Diabetes and Metabolic Syndrome..http://amzn.to/2e1RLA2 Order HEALTHY BODY START PAKS Click Here : http://bit.ly/2erR6bs AUDIO CREDIT Dead Doctors Don’t Lie Radio Show http://bit.ly/2ws7FML *Disclaimer: These statements have not been reviewed or approved by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Просмотров: 833 M Medeiros
Viatar CTC: Revolutionizing Cancer Testing and Therapy
 
06:22
Dave Gentry, host of "The RedChip Money Report", interviews Ilan Reich, Chairman & CEO of Viatar CTC Solutions (OTCQB: VRTT). Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters. Learn more at: http://www.redchip.com/company/healthcare/VRTT/279/medical-technology
Просмотров: 4631 RedChip Companies
Keynote Presentation: Molecular Testing for Hereditary-Familial Prostate Cancer and for Risk..
 
01:01:40
Presented At: Molecular Diagnostics Virtual Eve2018 Presented By: Judd W Moul, MD, FACS - James H Semans MD Professor of Surgery, Division of Urologic Surgery, Director, Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center Speaker Bio: Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research (CPDR); a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. In 2004, he completed a 26-year U.S. Army career, retiring as a full Colonel in the Medical Corps, and became Chief of the Division of Urologic Surgery at Duke. Serving as Chief from 2004 to 2011, he brought innovation and growth to the program. Most notably, he started the Duke Prostate Center, expanded the urology residency training program through a novel collaboration with the Department of Defense and was able to maintain Duke Urology as a top 10 program in the nation throughout his tenure. Webinar: Keynote Presentation: Molecular Testing for Hereditary-Familial Prostate Cancer and for Risk Assessment in Localized Disease Webinar Abstract: Prostate cancer is one of the most common cancers in men and a major health issue in the US and Worldwide. Until recently, prostate cancer was not felt to be a hereditary disease. However, up to 13% of men who present with de novo metastatic disease have a hereditary gene defect and men with a family history are also at risk for hereditary disease. The most common genes linked to hereditary prostate cancer include BRCA2, BRCA2, ATM, and CHEK2. In addition to hereditary genes, somatic mutations are common in advanced and castrate resistant disease and assessment in tumor and metastatic tissue is beginning to dictate novel therapeutics. Measurement of tumor derived messenger RNA expression panels is the basis of a number of commercially available molecular biomarker tests including Prolaris, Oncotype GPS, and Decipher. This presentation will highlight hereditary and somatic tumor testing and current practical considerations for clinical practice. Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/molecular-diagnostics-2018) 2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/molecular-diagnostics-2018) 3. Click Here to get your PACE (Expiration date –April 11, 2020 12:00 PM)– http://www.labroots.com/credit/pace-credits/2837/third-party 4. Click here to get your CME credits (Expiration date – 3 months from event) – https://www.surveymonkey.com/r/3N639M6 LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 34 LabRoots
New Diagnostic Tools for Prostate Cancer Screening
 
29:39
On Fathers’ Day, Dr. Deepak A. Kapoor, Founder and Past President of Integrated Medical Foundation spoke with Donna Vaughn about the new diagnostic tools used for prostate cancer screening. The information helps doctors in their recommendation regarding active surveillance vs. other treatment options.
Просмотров: 51 AUCOFNY1
GenomeDx Information for Life
 
01:43
GenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians. GenomeDx is developing and commercializing Decipher®, a highly validated genomic test for predicting metastatic disease in men with prostate cancer. In partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise. Using advanced cloud-based bioinformatics, GenomeDx mines the genomic data to develop proprietary tests that address key clinical questions in cancer patient management. GenomeDx has partnered to share genomic data with leading clinician-scientists worldwide to collaboratively enrich the knowledge and understanding of urologic cancers for the goal of improving global cancer patient care. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
Просмотров: 1718 GenomeDx
Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer
 
01:28
Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.
Просмотров: 62 OncLiveTV
Dr. David Samadi - PROSTATE CANCER NEWS - The Future of Postate Cancer Diagnostics
 
02:21
Internationally recognized Lenox Hill robotic prostate surgeon, Dr. David Samadi, continues to "walk the talk" with his quarterly patient newsletter. The latest issue takes a frank look at the prostate-specific antigen (PSA) test and the changing face of prostate cancer screening and prostate cancer treatment. RoboticOncology.com: August 2012 Newsletter - PSA Controversy and What You Need to Know About Prostate Cancer - Click Here http://www.roboticoncology.com/upload/Robotic-Oncology-Newsletter-August-2012.pdf The reputation of the PSA blood test seems to fluctuate monthly. Shortly after a U.S. government task force firmly advised against routine screening of healthy men, new reports emerge in support of the PSA. Some government data now points to PSA success in reducing the number of advanced-stage prostate cancer diagnoses by as much as three times. The newsletter is just another example of the lifelong commitment of care that Dr. Samadi and his team make to each patient. "Even when patients overcome prostate cancer, information is still vital," he stresses, "What we share with our patients could be infinitely helpful to other members of their family -- their brothers, their sons. We take that responsibility very seriously." Dr. Samadi routinely supports use of the PSA test, but in his summer newsletter he takes a candid look at just how far the PSA can take us and shares exciting news about the future of prostate cancer diagnostics. Dr. Samadi's PSA Evolution article touches on the heavily debated limitations of the PSA, chief among them its inability to accurately stage the disease upon diagnosis. Without precision regarding a man's prostate cancer severity, treatment decisions, including whether or not to have robotic prostatectomy surgery, are up to the surgeon's and patient's best call. With an eye to the future, Dr. Samadi gives patients a broad overview of prostate cancer screening advancements and how we may soon have the power to make even more informed treatment decisions. "We hear a lot about gene therapy," says Dr. Samadi, "and it truly is the future of medicine. Genetic analysis teaches us more about prostate cancer every day. Methodology involving CNVs and various proteins in the body are going to change the way we diagnose prostate cancer and fight it." Copy Number Variations (CNVs) in prostate cancer tumor cells are soon-to-be sources of guidance for predicting how the disease will progress, while SPDEF proteins are beginning to define what enables -- and ultimately, prevents -- metastases. The Robotic Oncology Newsletter also reminds patients how PSA Velocity Risk Count and post-treatment PSA screening contribute to lifelong wellness. Dr. David Samadi Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York and innovator of the SMART technique (Samadi Modified Advanced Robotic Technique) robotic prostatectomy surgery. Related Links: http://www.roboticoncology.com http://www.smart-surgery.com http://www.roboticoncology.com/upload/Robotic-Oncology-Newsletter-August-2012.pdf Related Videos: RoboticOncology.com: Prostate Cancer News http://www.youtube.com/watch?v=pwFoiVLc5UE&list=UUZvOHUgjV5EzAS-ZSOBeEGw&index=3&feature=plcp RoboticOncology.com: Prostate Cancer Screening Saves Lives http://www.youtube.com/watch?v=yPMcJFk09yk&list=UUZvOHUgjV5EzAS-ZSOBeEGw&index=8&feature=plcp Prostate Cancer Survivor, Patrick Walsh, Shares His Take on Beating Prostate Cancer http://www.youtube.com/watch?v=nFznpq3DLDE&list=UUZvOHUgjV5EzAS-ZSOBeEGw&index=10&feature=plcp SOURCE roboticoncology.com
Просмотров: 848 David B. Samadi M.D.
Viatar CTC Solutions: Addressing Cancer through New Therapeutic Technology
 
07:16
Dave Gentry, host of "The RedChip Money Report", interviews Ilan Reich, CEO of Viatar CTC Solutions (OTCQB: VRTT). Learn more at: http://www.redchip.com/company/healthcare/VRTT/279/medical-technology Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells (CTCs) from whole blood using label-free cross-flow filtration. It is designed to be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate, and gastric cancers. This proprietary technology also powers the Company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers, and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives. The Company’s liquid biopsy products are currently generating revenue, and sales are expected to increase in the coming quarters.
Просмотров: 2469 RedChip Companies
Prostate Cancer DREX KRISTI FINAL
 
00:31
Просмотров: 133 ProstateCancerBC
Prostate cancer treatment in France
 
02:55
French urologist on prostate cancer, robotic surgery, da Vince robot and tests for early detection of prostate cancer. Quality treatment of prostate cancer in France at affordable prices with Medifrance Solution. Medifrance Solution is your guide to the #1 healthcare system in the world 🇫🇷 🔵 High-quality diagnostics & treatment 🏥 ⚪️ Wonderful travel memories 🗼🍷👠 🔴 Affordable prices 💰 Contact us at contact@medifrancesolution.com For more information visit http://www.medifrancesolution.com Social: Facebook https://www.facebook.com/medifrancesolution Instagram https://www.instagram.com/medifrance_solution Twitter https://twitter.com/medifrasolution Song: Christine And The Queens - Paradis perdus (Karaoké version)
Treating Prostate Cancer with Green Tea
 
04:52
Green tea is put to the test against precancerous lesions, prostate cancer and metastatic cancer and compared to the effects of black tea. Subscribe to Dr. Greger’s free nutrition newsletter at http://www.nutritionfacts.org/subscribe and get a free excerpt from his latest NYT Bestseller HOW NOT TO DIE. (All proceeds Dr. Greger receives from the sales of his books, DVDs, and speaking engagements go to support the 501c3 nonprofit that runs NutritionFacts.org.) What if you packed your diet with all sorts of plant foods? See Cancer Reversal through Diet (http://nutritionfacts.org/video/cancer-reversal-through-diet/). The problem is Changing a Man’s Diet After a Prostate Cancer Diagnosis (http://nutritionfacts.org/video/changing-mans-diet-prostate-cancer-diagnosis/). What about preventing prostate cancer in the first place? That was the subject of my last video, Preventing Prostate Cancer with Green Tea (http://nutritionfacts.org/video/preventing-prostate-cancer-with-green-tea). Similar studies were done with pomegranates. Check out the results in Pomegranate vs. Placebo for Prostate Cancer (http://nutritionfacts.org/video/pomegranate-vs-placebo-for-prostate-cancer/). Have a question about this video? Leave it in the comment section at http://nutritionfacts.org/video/treating-prostate-cancer-with-green-tea and someone on the NutritionFacts.org team will try to answer it. Want to get a list of links to all the scientific sources used in this video? Click on Sources Cited at http://nutritionfacts.org/video/treating-prostate-cancer-with-green-tea. You’ll also find a transcript of the video, my blog and speaking tour schedule, and an easy way to search (by translated language even) through our videos spanning more than 2,000 health topics. If you’d rather watch these videos on YouTube, subscribe to my YouTube Channel here: https://www.youtube.com/subscription_center?add_user=nutritionfactsorg Thanks for watching. I hope you’ll join in the evidence-based nutrition revolution! -Michael Greger, MD FACLM http://www.NutritionFacts.org • Subscribe: http://www.NutritionFacts.org/subscribe • Donate: http://www.NutritionFacts.org/donate • HOW NOT TO DIE: http://nutritionfacts.org/book • Facebook: http://www.facebook.com/NutritionFacts.org • Twitter: http://www.twitter.com/nutrition_facts • Instagram: http://instagram.com/nutrition_facts_org/ • Google+: https://plus.google.com/+NutritionfactsOrgMD • Podcast: http://nutritionfacts.org/audio/
Просмотров: 43042 NutritionFacts.org
Ucsf Prostate Cancer - What's New In Prostate Cancer Treatment? | Dana-Farber Cancer Institute
 
02:11
Ucsf Prostate Cancer - What's New In Prostate Cancer Treatment? | Dana-Farber Cancer Institute. For alternative option go to https://wp.me/p9xQ8n-55 ucsf prostate cancer - prostate cancer overview. ucsf prostate cancer radiation Or poster at the annual UCSF Prostate Cancer research retreat 2013 UCSF Prostate Cancer Retreat ucsf prostate cancer nomogram The authors thank Jeanette Broering, Hazel Dias, Alex Ignatov, Sarah Joost and Frank Stauf for operating and managing the UCSF Urologic Oncology Outcomes Database and Nannette Perez for supporting the UCSF prostate cancer active surveillance cohort The hallmark of research in the UCSF Prostate Cancer Program is innovative scientific approaches to important problems in prostate cancer. Prostate cancer decisions: mayo clinic radio. Esmo 2017: prostate cancer highlights. Lifestyle and Diet May Stop or SuMMarY heaLthY proState CaNCer diet 23 frequently asked Questions University of California, San Francisco Patient Advocates Stan Rosenfeld, ucsf prostate cancer diet. He is the leader of the Genitourinary Medical Oncology Program and an investigator with the UCSF Prostate Cancer Program. The hallmark of research in the UCSF Prostate Cancer Program is innovative scientific approaches to important problems in prostate cancer. 2015 UCSF Prostate Cancer Program Retreat. The authors thank Jeanette Broering, Hazel Dias, Alex Ignatov, Sarah Joost and Frank Stauf for operating and managing the UCSF Urologic Oncology Outcomes Database and Nannette Perez for supporting the UCSF prostate cancer active surveillance cohort. Search Results For: ucsf prostate cancer active surveillance. Poster presentation, UCSF Prostate Cancer Retreat, San Francisco, CA, on May 23, 2011 PROCEEDINGS: 1993 Wyeth Pediatrics: Pediatric and adolescent gynecology: a challenge for the '90s. 3/01: UCSF Prostate Cancer Retreat, “Interrupting assembly of nuclear hormone receptor transcriptional activation complexes: Implications for drug development”. Place Clinical Science Poster, UCSF Prostate Cancer Retreat. June 16, 2010, Josh Stuart, UCSF Prostate Cancer Retreat. 6/01-5/02: Co-PI (with Robert Fletterick), UCSF Prostate Cancer Research Program, “Novel. Best Poster presentation award at the Annual UCSF prostate Cancer Research Retreat-2016. Or poster at the annual UCSF Prostate Cancer research retreat. 2011 UCSF Prostate Cancer Research Retreat. 5 Million for UCSF Prostate Cancer Research. Search Results For: ucsf prostate cancer radiation. Expert opinions in prostate cancer brazil 2017. What's new in prostate cancer treatment? Patients with advanced prostate cancer are currently treated with combinations and sequences of immunotherapies hormonal approaches and chemotherapy. Freedland presented "nutrition and prostate cancer: what we think we know and what we actually know" at the 22nd annual scottsdale prostate cancer symposium on thursday march 16 2017. Nutrition and prostate cancer what we think we know and what we actually know. Body rig research highlights - treatment of prostate cancer at ucsf using different tools and techniques such as hifu prostate hyperthermia micropet / ct images of psma and hyperpolarized c-13 mr. Localized prostate cancer: progress toward personalized care. Rethinking prostate cancer at ucsf with matthew cooperberg, md. In the era of prostate cancer screening mortality rates have fallen 40 percent. In the era of prostate cancer screening mortality rates have fallen 40 percent. In the era of prostate cancer screening mortality rates have fallen 40 percent. Viewing prostate cancer aggressiveness in a unique way. #UcsfProstateCancer ucsf prostate cancer treatment, ucsf prostate cancer diet, ucsf prostate cancer clinical trials, stanford prostate cancer, ucsf prostate cancer program, ucsf lung cancer doctors, ucsf prostatectomy Reference: https://youtu.be/dU-E-_axrZc https://www.youtube.com/playlist?list=PLLmSMVj8_5y8Mt-0eXZtUt67k3ad2OGOW https://en.wikipedia.org/wiki/Prostate_cancer https://en.wikipedia.org/wiki/University_of_California,_San_Francisco https://www.youtube.com/watch?v=oU-BAjUppfU
Просмотров: 2602 Best Tongkat Ali
FoundationOne CDx: A Broad Companion Diagnostic Test for Cancer Tumors
 
01:14
Vincent Miller, MD, chief medical officer of Foundation Medicine, Industry Innovation Awardee, discusses FoundationOne CDx, an FDA-approved diagnostic that is clinically validated for solid tumors.
Просмотров: 231 Rare Disease Report
Prostate Cancer Screening - Diagnostic Promises and USPSTF Challenges - Congressional Briefing
 
01:00:07
Congressional Briefing In collaboration with the Congressional Men’s Health Caucus and Prostate Cancer Task Force - Congressmen Markwayne Mullin (OK) and Donald Payne, Jr. (NJ) (Co-Chairs) 1. Opening Remarks Ana N. Fadich – Introduction, VP, Men’s Health Network Congresswoman Marsha Blackburn, 7th District, Tennessee 2. Speakers Deepak A. Kapoor, MD, Chairman and CEO, Integrated Medical Professionals Serge Ginzburg, MD, FACS, Director, Einstein Prostate Cancer Center, Department of Urology, Albert Einstein Medical Center Peter M. Knapp, MD, Co-Founder and Director, Strand Diagnostics Darrell Sabbs, Community Benefit Manager/Legislative Affairs, Phoebe Putney Health System 3. Comments Bernard Wooden, Patient Advocate, Men's Health Network Tony Goodman, Patient Advocate, Men's Health Network http://www.PCaAwareness.com http://www.ProstateHealthGuide.com http://www.ProstateCancerAwarenessMonth.com
Просмотров: 145 MHNMedia
Lung cancer - causes, symptoms, diagnosis, treatment, pathology
 
12:16
What is lung cancer? Lung cancer, or lung carcinoma, is the uncontrolled division of epithelial cells which line the respiratory tract. Find more videos at http://osms.it/more. Hundreds of thousands of current & future clinicians learn by Osmosis. We have unparalleled tools and materials to prepare you to succeed in school, on board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. Subscribe to our Youtube channel at http://osms.it/subscribe. Get early access to our upcoming video releases, practice questions, giveaways, and more when you follow us on social media: Facebook: http://osms.it/facebook Twitter: http://osms.it/twitter Instagram: http://osms.it/instagram Our Vision: Everyone who cares for someone will learn by Osmosis. Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission Medical disclaimer: Knowledge Diffusion Inc (DBA Osmosis) does not provide medical advice. Osmosis and the content available on Osmosis's properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.
Просмотров: 92239 Osmosis
Advancements in the diagnosis and treatment of patients with prostate cancer
 
16:13
Professor Heather Payne chairs a discussion with Professor Kurt Miller, Ms Netty Kinsella and Professor David Dearnaley around advancements in the diagnosis and treatment of patients with prostate cancer. Discussions around diagnosis highlighted the results of the PROMIS trial; with multiparametric MRI allowing more men with clinically insignificant disease to avoid biopsy. Active surveillance was also discussed as an important tool for the treatment of men with early or low risk disease. Conversations around diagnosis for advanced disease focused around PSMA scanning which is perceived by the experts to have provided significant advancements in terms of specificity and sensitivity of diagnosis. The group also discuss data around treatment of oligometastatic disease and the potential use of biomarkers and next generation sequencing in precision medicine, as well as the use of chemotherapy and abiraterone in combination with ADT as a promising treatment for patients with castration sensitive disease. Looking to the future of treatment of patients with prostate cancer, the experts discuss the treatment of locally advanced disease and the use of abiraterone and docetaxel in this patient group. The importance of further understanding optimal combinations of treatment modalities for individual patients is also highlighted. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 149 ecancer
Prostate Cancer Genes
 
01:17
http://mymediclique.com reviews some of the new findings on liquid biopsies and prostate cancer gene mutations
Просмотров: 5931 Mymediclique
Bladder Cancer
 
01:16:06
(Visit: http://www.uctv.tv/) Bladder cancer is the 5th most common cancer and is much more common in smokers. UCSF genitourinary cancer specialist Dr. Terence Friedlander reviews the basic biology and pathophysiology of bladder cancer, focusing on methods used to detect bladder cancer, treatment of early-stage disease with therapies administered into the bladder, the role of surgery or radiation therapy in the treatment localized disease, the role of chemotherapy for metastatic disease, and new directions in the field, particularly the role of immunotherapy in bladder cancer. Recorded on 06/24/2014. Series: "UCSF Osher Center for Integrative Medicine presents Mini Medical School for the Public" [9/2014] [Health and Medicine] [Show ID: 28499]
Просмотров: 100938 University of California Television (UCTV)
Decipher® Test
 
01:48
The Decipher® test informs more accurate decisions to support post surgical management of prostate cancer. Validated in over 2,000 patients, the Decipher test accurately predicts the probability of metastasis and provides an independent assessment of tumor aggressiveness; information distinct from that provided by Gleason score or PSA. Clinical studies from leading cancer centers published in over a dozen medical journals demonstrate that Decipher can accurately predict metastatic disease, which men may benefit from radiation therapy following prostate surgery, and can lead to significant cost-savings for healthcare systems. Decipher was developed in partnership with the Mayo Clinic. Decipher is covered by Medicare and multiple private insurance plans and is available to eligible US patients through their physicians.
Просмотров: 5949 GenomeDx
Cancer Genetic Testing at the Crossroads
 
57:26
Genomic sequencing technologies have enabled increasing use of cancer genetic testing for both inherited cancer predisposition and somatic mutation profiling in tumors. This presentation reviews interplay between germline and somatic findings in cancer genetic testing, with particular emphasis on new areas of clinical utility. These new areas include germline testing of cancer predisposition genes to guide cancer treatment decisions, tumor DNA sequencing to rule out Lynch syndrome, and tumor DNA sequencing used to inform germline variant classification. Colin C. Pritchard, MD, PhD Associate Professor Director of Clinical Diagnostics, Brotman Baty Institute for Precision Medicine Co-Director, Genetics and Solid Tumors Laboratory Head, Genetics Division Dept. of Laboratory Medicine University of Washington 10/17/18 http://depts.washington.edu/labweb/Education/ContEdu/ http://uwtv.org
Просмотров: 52 UW Video
What are the Signs and Symptoms of Prostate Cancer?
 
02:34
Find out the signs and symptoms of prostate cancer from Cancer Research UK. Learn how prostate cancer is diagnosed and the tests needed to find out. http://www.cancerresearchuk.org/about-cancer/prostate-cancer/symptoms In the video, Dr. Vincent Gnanapragasm from Cambridge University talks us through prostate cancer symptoms, signs and types: "As the most common cancer in men understanding Prostate Cancer is vital. So I’ve come to Cambridge University hospital to speak with Dr. Vincent Gnanapragasam to find out how they go about diagnosing this common cancer. Well Vincent, Prostate Cancer is notoriously difficult to diagnose isn’t it. Indeed, in fact Prostate Cancer most often has no symptoms. A man might go to his GP because he has notice a change in his urinary symptoms, getting up at night maybe or having difficulty passing water. And most often that’s due to a normal enlargement of the prostate as he gets older. In fact prostate cancer doesn’t cause any symptoms unless it is very advanced. In which case it might mimic some of those symptoms of an obstructed or large prostate. But if there are any concerns the first step is to go and see your GP who can then investigate further. What would your GP do? - Take a history - Do a physical examination - PSA blood test So what would your GP do? Most often they’ll take a history from you, do an examination of the prostate and do a PSA blood test. What is a PSA test? So PSA stand for Prostate Specific Antigene. It’s produced by the prostate gland and it’s a marker for the presence of Prostate Cancer. However it can also be raised by other conditions so it’s not a very specific marker but it’s the first test that we can do to see whether we should proceed to further investigations. What is a PSA test? A blood test that measures the amount of prostate specific antigen (PSA) in your blood. So what happens if you get sent to the hospital for an examination? The specialist will see you, again take a history and an examination and then most often what they will do is arrange a prostate biopsy. Increasingly they might recommend a scan to be done first, an MRI scan and then discuss with you what the best way to do a biopsy is. What is a Biopsy? The removal of a small sample of tissue for examination to determine the presence or extent of a disease. And if it is cancer tell us what happens then, tell us about some of the tests. Well, a discussion then starts. The first step is to make sure we know exactly what kind of Cancer it is and that might involve other types of scans, for example a CT scan or a bone scan. The kind of Cancer is determined by the size of it or the stage of a cancer. And once the specialist puts all that information together with what the biopsy has shown then they start to discuss with you what the treatments are."
Просмотров: 57417 Cancer Research UK
What is PET-CT? For prostate cancer follow-up
 
06:38
http://www.whatisnuclearmedicine.com/ http://aipes-eeig.org/ Nuclear Medicine was introduced shortly after radioactivity was discovered. After 50 years of experience and practice, today Nuclear Medicine plays a key role in the evolution of medicine concerning both diagnostic and therapeutic techniques. While Nuclear Medicine techniques are routinely employed with high quality and safety standards, the discipline itself remains complex and needs to be carefully explained. The usefulness of such techniques is testified by the 60 million procedures performed worldwide on a yearly basis. To know more, click here : http://www.whatisnuclearmedicine.com/ This video is copyrighted by AIPES To use this video, please contact us : admin@aipes-eeig.org AIPES represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe. The combination of radiopharmaceuticals & state-of the art imaging permits non invasive visualisation of organs ,function & structure within the body. Nuclear medicine is used in the diagnosis, management, treatment & prognosis of diseases across a broad range of medical specialties, such as oncology, cardiovascular & neurology to name a few and as such is an integral part of patient care.
Просмотров: 1498 navalorama
Advanced prostate cancer overview: Expert discussion
 
17:29
Dr Payne (University College Hospital, London, UK) chairs a discussion for ecancertv with Prof Danesi (University of Pisa, Pisa, Italy), Prof da Costa (Hospital de Santa Maria, Lisbon, Portugal) and Prof Mulders (Radboud University, Nijmegen, The Netherlands) about the main points coming from the 2016 Prostate Debate in Copenhagen. In particular, they discuss the role of docetaxel chemotherapy in hormone-sensitive prostate cancer and the role of drug combinations such as zoledronic acid and celecoxib. They discuss the impact of the STAMPEDE trial, along with discussion of androgen deprivation therapy, COX inhibitors and side effects. They also consider less invasive diagnosis and monitoring methods which harness blood-based biomarkers. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 176 ecancer
Dr. Petrylak Discusses Sequencing Prostate Cancer Therapies
 
01:43
Daniel Petrylak, MD, Professor of Medicine, Co-Leader of Prostate Cancer, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses a need to create a solid guideline for sequencing castrate-resistant prostate cancer (CRPC) therapies. Petrylak explains there is currently very little information to help clinicians determine the order of treatment for CRPC. There are 5 drugs that are currently on the market, or will soon be on the market, for very similar clinical niches within this disease. These drugs include the chemotherapy microtubule inhibitor cabazitaxel (Jevtana), androgen receptor antagonists such as the recently approved abiraterone acetate (Zytiga) and the investigatory MDV3100, the exploratory alpha-emitting radiopharmaceutical radium-223 (Alpharadin), and the immunotherapy sipuleucel-T (Provenge) that can be given to patients that fail docetaxel (Taxotere), or have had one docetaxel regimen. Without a thorough understanding of the biology of these drugs it is difficult to know how they should be sequenced. Petrylak feels that a test should be developed that indicates which drug or treatment is the best in any given situation. Without a test clinicians can only use their best judgment and usually prescribe chemotherapy to rapidly progressive patients and hormonal agents for chemotherapy resistance. The lack of a scientific method to decide the treatment has led to disappointment within the oncology community and will be the focus of study in the future.
Просмотров: 712 OncLiveTV
Prostate Cancer Breakthrough | UCLA Health
 
02:23
Video courtesy of NBC Learn more at http://urology.ucla.edu
Просмотров: 2915 UCLA Health
ESMO 2017: New prostate data from STAMPEDE
 
23:21
This expert to expert discussion focuses on new data from the STAMPEDE trial. Data released at ESMO 2017 looks to answer whether the addition of abiraterone acetate plus prednisolone (AAP) improves outcomes vs. docetaxel for patients with high risk prostate cancer. A second abstract then evaluated whether the addition of AAP improves outcomes for patients with M0 disease. Both speakers highlight current UK and German approval and reimbursement status and hypothesised that patients would prefer to have hormone based treatments over chemotherapy options despite the increased duration of therapy and routine scheduling of follow up visits. The experts touch on PSMA radio-tagged diagnostics and the balance of an active dose and minimising patient side effects. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 203 ecancer
Dr. Satu Vainikka, CEO - Valirx (VAL)
 
27:50
Valirx (VAL) Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. ________ Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only. - Directors present their latest plans regarding development and growth. - An opportunity to talk directly to the companies and personally put forward your questions. -The chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutions www.sharesmagazeine.co.uk/events
Просмотров: 374 Shares Magazine
Reducing the Harm of Prostate Cancer Screening
 
05:04
Dr. Rodney Breau, a Surgical Urologic Oncologist and Associate Professor of Epidemiology from The Ottawa Hospital in Canada, shares results of his study appearing in the January 2016 issue of Mayo Clinic Proceedings, which demonstrates the benefits of repeating PSA screenings prior to performing biopsies after a first test indicates positive findings. Available at: http://tinyurl.com/pdyngov
Просмотров: 213 Mayo Proceedings
KILL CANCER IN LESS THAN AN HOUR! HERE IS HOW!
 
02:30
KILL CANCER IN LESS THAN AN HOUR! HERE IS HOW! Please like my Facebook page- https://www.facebook.com/AMYHomecures ----------------------------------------------------------------------------------------------------------- Subscribe to my channel: https://goo.gl/UufjKr ----------------------------------------------------------------------------------------------------------- Disclaimer: The materials and the information contained on Natural Cures channel are provided for general and educational purposes only and do not constitute any legal, medical or other professional advice on any subject matter. These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always seek the advice of your physician or other qualified health provider prior to starting any new diet or treatment and with any questions you may have regarding a medical condition. If you have or suspect that you have a medical problem, promptly contact your health care provider. ----------------------------------------------------------------------------------------------------------- Don't miss these videos: 2 TABLESPOONS A DAY OF THIS MIRACLE ADN NEVER NEED TO GO TO THE GYM AGAIN!!! https://youtu.be/2AcP271PoR0 SHE APPLIES VICK VAPORUB ON HER FEET BEFORE BED; WHEN YOU KNOW THE REASON, YOU WILL DO THE SAME!! https://youtu.be/sQXAhx53aNo USE THIS OIL FOR FAST HAIR, EYEBROWS, AND EYELASHES GROWTH !! https://youtu.be/BZwKngY_Pj0 WARNING DON’T EVER THROW OUT SPROUTED GARLIC (HERE’S WHY) https://youtu.be/STTkFHGv8cg DRINK TURMERIC GOLDEN MILK TO FLUSH LIVER TOXINS OVER NIGHT! ! https://youtu.be/LoKe19JTVDA 5 NIGHTS OPEN CHALLENGE – ALL DARK/BLACK SPOTS WILL DISAPPEAR FROM YOUR FACE !! https://youtu.be/l9tnAX8QfVE DOCTORS ARE SHOCKED! THIS AMAZING DRINK CAN CURE DIABETES IN JUST 5 DAYS! https://youtu.be/gSVYl1nGKjc HOW TO REMOVE BLOATED BELLY IN JUST 60 SECONDS WITH THIS INCREDIBLE BELLY-FAT BURNING RECIPE!! https://youtu.be/q_htT7q-Uow TRY THESE REMEDIES TO GET RID OF PAIN CAUSED DURING PERIODS|Natural Remedies for Menstrual Cramps https://youtu.be/cezEGy_bPJg IF YOU WANT TO MAKE YOUR LIVER 20+ YEARS YOUNGER, JUST CONSUME THIS FRUIT! https://youtu.be/C8GSYqvGsII I LOST 146 POUNDS IN 6 MONTHS, THIS 2 INGREDIENT DRINK REALLY WORKS MIRACLE FOR WEIGHT LOSS !!! https://youtu.be/1cn3k5gHDc0 DOCTORS ARE SHOCKED! THIS AMAZING DRINK CAN CURE DIABETES IN JUST 5 DAYS! https://youtu.be/gSVYl1nGKjc DOCTORS ARE SPEECHLESS BOILING ONLY TWO INGREDIENTS WILL HELP YOU LOSE ALL OF YOUR BODY FAT RAPIDLY https://youtu.be/lDTzcYJqrDk DO THIS AND YOU WILL LOOK 10 YEARS YOUNGER! https://youtu.be/_IoaUvSzzlw THIS MIRACULOUS GRASS HEALS PARALYSIS AND OTHER DISEASES, SEE HOW TO PREPARE IT! https://youtu.be/avYHKcbp9oI Doctors advised that tomato can Prevent Prostate Cancer easily !! https://youtu.be/SXT56EnCsOg PUT THESE 2 INGREDIENTS IN YOUR COFFEE. AFTER JUST 2 SIPS, YOUR BELLY FAT WILL DISAPPEAR !! https://youtu.be/vqVBBhhqSEQ LEMON, PEPPER AND SALT IS A BETTER CURE THAN REGULAR MEDICINES! CAN TREATS 9 PROBLEMS!! https://youtu.be/X7hwC8qY5H0 IF YOU WANT TO MAKE YOUR LIVER 20+ YEARS YOUNGER, JUST CONSUME THIS FRUIT! https://youtu.be/C8GSYqvGsII Drinking Apple Cider Vinegar Before Bedtime Will Change Your Life For Good! https://youtu.be/J1YVGhndSCg SAY GOODBYE TO WRINKLES AND SAGGING FACIAL SKIN AFTER WASHING IT WITH THIS POWERFUL MIXTURE! https://youtu.be/JhOa4r2aIGw The fruit that can rejuvenate liver and make it 20 years younger!! https://youtu.be/PQj-RJ6rD4g THE PLANT, WHICH KILLS 100% CANCER CELLS | 10,000 TIMES STRONGER THAN CHEMOTHERAPY! https://youtu.be/KtriBmLBtw0 10 COMMON HEALTH PROBLEMS THAT CAN BE TREATED USING EPSOM SALT https://youtu.be/uAg7tVNt1MA This Plant Kills 14 Types Of Cancer And 13 Different Infections! So Why Don’t Doctors Recommend It? https://youtu.be/96Z2DDWCl1s Only 3% Of People Have The Letter X On Their Both Hands. Here’s What It Means About Your Destiny!! https://youtu.be/YPUKbN001QE Just Boil These Two Ingredients And You Will Quickly LOSE BELLY FAT! https://youtu.be/Ymjy6_g7Clw What does your sitting position talk about your personality?! https://youtu.be/WNu41Q9xPRU WEARING SOCKS WHEN GOING TO BED CAN IMPROVE YOUR SEX LIFE.. https://youtu.be/oqAnHZpKMYw HERE ARE THE SIGNS OF STOMACH CANCER YOU SHOULD PAY ATTENTION TO. https://youtu.be/GpWwg9tkNIU She Squeezed A Lemon In One Spoonful Of Olive Oil And Then Never Stopped Using It https://youtu.be/yXzbI4cqO9M HALF A LEMON DIPPED IN BAKING SODA CAN DO MIRACLES TO YOUR BODY, THIS IS NOT A JOKE.!! Tags Used: unhealthy food,symptoms of liver cancer,stage 4 lung cancer,skin cancer,prostate cancer,pancreatic cancer,ovarian cancer,oncology,non small cell lung cancer,liver cancer,healthy food,head and neck cancer,harmful foods,diet food,colon cancer,cervical cancer,cancer sign,cancer research,cancer,breast cancer stages,breast cancer signs,breast cancer,bladder cancer symptoms,american cancer society,bht preservative
Просмотров: 564029 AMY. Homecure
Dr. Paulson on When to Consider Lutathera in Patients With NETs
 
01:55
Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses when to consider using Lutathera in patients with neuroendocrine tumors (NETs).
Просмотров: 203 OncLiveTV
Genetic test predicts aggressiveness of prostate cancer
 
01:24
A new gene test may help identify slow-growing prostate cancers that will require treatment, a new study suggests. The test revealed the levels of "expression" of three aging-related genes and could be used to predict whether seemingly slow-growing prostate cancer will remain slow-growing, according to Columbia University Medical Center researchers. Using the three-gene test along with existing cancer-staging tests could help doctors better determine which men with early prostate cancer can be safely monitored and spared the potential risks of prostate removal or other invasive treatments, the study authors suggested. The investigators assessed the test in 43 prostate cancer patients who had been monitored for at least 10 years. All of the men had initially been diagnosed with low-risk cancer, but 14 eventually developed advanced prostate cancer. All 14 of those patients were correctly identified by the three-gene test, according to the study, which was published online Sept. 11 in the journal Science Translational Medicine. The researchers plan to conduct a larger study to assess the test's accuracy. "Most of the 200,000 prostate cancers diagnosed each year in the U.S. are slow-growing and will remain so, but the three-gene biomarker could take much of the guesswork out of the diagnostic process and ensure that patients are neither overtreated nor undertreated," study leader Cory Abate-Shen, a professor of urological oncology at Columbia University Medical Center, said in a university news release. And, as study co-author Dr. Mitchell Benson, chairman and professor of urology at the medical center, explained in the news release: "The problem with existing tests is that we cannot identify the small percentage of slow-growing tumors that will eventually become aggressive and spread beyond the prostate." Currently, men diagnosed with low-risk prostate cancer can choose either active surveillance, which includes regular testing and monitoring but risks missing the window when the disease is localized and potentially curable, or aggressive treatment, which can cause serious side effects such as urinary incontinence and impotence. Dr. Louis Kavoussi is chairman of urology at North Shore-LIJ's Arthur Smith Institute for Urology in New Hyde Park, N.Y. He said: "Men getting a diagnosis of prostate cancer are initially shocked and begin conjuring images of themselves as desperate, dying patients. In reality, the majority of patients with prostate cancer do not die of the disease, and a large portion can be managed with observation. This study looks at novel molecular tools to help define which patients can be managed conservatively, and avoid potential side effects and expensive treatments." Dr. Aaron Katz, chairman of urology at Winthrop-University Hospital in Mineola, N.Y., said: "In the current era, it is clear that PSA screening has detected many men with prostate cancer. In the years past, we believed that all men needed to be treated. The good news is that many men who are found to have these abnormal cells in their prostate may not need any treatment. With advances in genomics and DNA testing, we are now able to stratify those men with indolent disease, and prevent unnecessary treatment."
Просмотров: 383 Heath and Beauty
Visiopharm: Connectivity Based Her2 IHC Membrane Image Analysis  in Gastric Cancer
 
26:35
In 2009, Her 2 targeted therapy for gastric and gastro-oesophageal (G/GEJ) cancers became a reality for the first time with the presentation of the TOGA trial results at ASCO. Results of the TOGA trial placed a new focus on assessment of Her 2 status in these cancers. Although testing had been established for breast cancer there are significant differences between scoring of Her 2 immunohistochemistry between G/GEJ and breast cancers. There is significant heterogeneity in G/GEJ cancers and incomplete membrane staining is common and rarely seen in breast. For breast cancer, the HER2-CONNECT method has been CE-marked for in-vitro diagnostic use. This method provides a generalized (and continuous) measure of circumferential membrane staining across tumor cells. The aims of this study were to explore the feasibility of using the connectivity principle for gastric cancers, to define suitable cut-offs for analysis and assess whether we can reduce the number of 2+ cases without compromising patient outcomes. In a retrospective study of 44 cases from St. James’s Hospital Dublin the connectivity principle was found useful for determining HER2 status, based on the protein expression in gastric cancer patients. The cut-offs for determining negative versus positive HER2 status were found to be different (lower) reflecting the known difference in membrane morphology. Similar to findings for breast cancer, it was possible to reduce the number of 2+ cases by 77% without loss of accuracy (sensitivity/specificity) with respect to gene amplification. When excluding 2+ cases the concordance with manual reading is 100%.This study will now be taken forward as a prospective study. About our Speaker Dr. Stephen Finn is an academic Histopathologist with subspecialist interests limited to genitourinary pathology and cancer molecular diagnostics. He is a Prostate Cancer Foundation Young Investigator and co-director of the Cancer Molecular Diagnostic Laboratory at St James’s Hospital and Associate Professor of pathology at the University of Dublin, Trinity College. Dr. Finn qualified from University College, Cork (UCC) in 1998, completed his higher professional training in Dublin in 2005 and subsequently worked as staff pathologist and Senior Scientist at the Centre for Molecular Oncologic Pathology (CMOP) at the Dana Farber Cancer Institute in Boston, USA. He returned to Ireland in 2008 and worked as consultant pathologist at the Mid Western Regional Hospital Limerick before moving to his current position. He has PhD from Trinity College Dublin (2005) and is a Fellow of the Royal College of Pathologists, UK and a Fellow of the Faculty of Pathology of the Royal College of Physicians of Ireland. Dr. Finn is member of the steering Committee of the Transdisciplinary Prostate Cancer Partnership (ToPCaP). His specific research interests are related to image analysis in pathology, non-coding RNA signatures in aggressive prostate cancer and the role of the Circulating Tumor Cell in progression to metastasis.
Просмотров: 1038 Visiopharm
Highly-advanced minimally-invasive prostate cancer diagnosis and treatment
 
05:15
Xavier Garcia-Rojas, M.D., Ph.D., M.B.A and Carlos R. Hamilton III, M.D. of Laser Prostate Centers of America discuss the highly-advanced, minimally-invasive biopsy and treatment options including MRI-guided biopsy and focal laser ablation (FLA) that has a reduced risk of side effects.
Просмотров: 375 Laser Prostate Centers of America
Flaws in PLCO and Other Prostate Cancer Studies Explained at Congressional Briefing
 
05:32
Drs. Deepak A. Kapoor, Serge Ginzburg, and Peter M. Knapp explain the serious flaws in the Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) during the Q & A session of the Congressional Briefing. Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) European Randomized study of Screening for Prostate Cancer (ERSPC) Congressional Briefing In collaboration with the Congressional Men’s Health Caucus and Prostate Cancer Task Force - Congressmen Markwayne Mullin (OK) and Donald Payne, Jr. (NJ) (Co-Chairs) 1. Opening Remarks Ana N. Fadich – Introduction, VP, Men’s Health Network Congresswoman Marsha Blackburn, 7th District, Tennessee 2. Speakers Deepak A. Kapoor, MD, Chairman and CEO, Integrated Medical Professionals Serge Ginzburg, MD, FACS, Director, Einstein Prostate Cancer Center, Department of Urology, Albert Einstein Medical Center Peter M. Knapp, MD, Co-Founder and Director, Strand Diagnostics Darrell Sabbs, Community Benefit Manager/Legislative Affairs, Phoebe Putney Health System 3. Comments Bernard Wooden, Patient Advocate, Men's Health Network Tony Goodman, Patient Advocate, Men's Health Network http://www.PCaAwareness.com http://www.ProstateHealthGuide.com http://www.ProstateCancerAwarenessMonth.com
Просмотров: 190 MHNMedia
Dr. George Morris, Chief Operations Officer of Valirx (VAL) at SHARES Investor Evenings
 
33:07
Valirx (VAL) Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.
Просмотров: 707 Shares Magazine
Dr. Daniel Petrylak Describes the Clinical Investigation of PROSTVAC in Prostate Cancer
 
00:48
Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer (CRPC). For more prostate cancer resources, visit http://www.onclive.com/specialty/prostate-cancer
Просмотров: 239 OncLiveTV
Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets
 
03:22
Dr McKay talks to ecancertv at ASCO GU 2016 about her research in to the impact of symptomatic skeletal events (SSE) in castration resistant prostate cancer (CRPC) patients. Prostate cancer patients frequently develop bone metastases, leading to symptomatic skeletal events. The study evaluated the impact of SSE on healthcare resource utilization, health-related quality of life, and pain. The economic and quality of life burden of SSE amongst CRPC patients with bone metastases is high, underscoring the need for preventive treatments for SSE in this population.
Просмотров: 47 ecancer
Biotech Company Focus: MabVax Therapeutics (NASDAQ: MBVX)
 
08:49
$MBVX - SCN's Jane King sits down with CEO David Hansen of MabVax Therapeutics (NASDAQ: MBVX), and guest analyst Jeffrey Kraws of Crystal Research Associates, to discuss the biotech company and it's future outlook. http://www.mabvax.com/ MabVax is a clinical stage biotechnology company. We have discovered and are developing novel human antibody based products for the diagnosis and treatment of metastatic solid tumor cancers. We have created a platform technology to discover antibodies from patient immune responses against their cancers. We now have a portfolio of fully human antibodies that are being developed to address unmet medical needs in several difficult to treat cancers such as pancreatic, small cell lung, sarcoma, ovarian, and breast cancer. Our lead antibody development program is HuMab-5B1 and we started two clinical trials this year with a therapeutic agent (MVT-5873) and as a new generation PET imaging product (MVT-2163). In addition, we have identified a radioimmunotherapy agent (MVT-1075) and we plan to file an Investigational New Drug Application (NDA) with the FDA later this year. Clinical Trials MVT-5873: MVT-5873 (HuMab-5B1) is our therapeutic antibody. The Phase I trial began in the first quarter of this year to evaluate the safety, tolerability and pharmacokinetics as a single agent or in combination with a standard of care chemotherapy. The trial is underway in subjects with metastatic pancreatic cancer or other CA19-9 positive malignancies. MVT-2163: MVT-2163 89Zr-HuMab-5B1 is our positron emission tomography (PET) imaging agent. The Phase I trial began in the second quarter of this year at Memorial Sloan Kettering Cancer Center. In preclinical models this imaging agent demonstrated high-resolution images of tumors in xenograft animal models, and is now being evaluated in human clinical trials as an important new tool to aid in the diagnosis, monitoring and assessment of patients with pancreatic cancer. MVT-2163 is planned for evaluation as companion diagnostic with MVT-5873.
Просмотров: 6290 BGN - Blockchain Global News
Best of ASCO GU 2016 prostate cancer data
 
13:04
Prof Clarke (The Christie Hospital, Manchester, UK) chairs a discussion with Dr Payne (University College Hospital, London, UK) and Prof Iversen (Copenhagen Prostate Cancer Center, Copenhagen, Denmark) for ecancertv about the highlights in prostate treatment arising from ASCO GU 2016. They discuss the results and implications of data coming from RTOG 0415, a randomised phase III non-inferiority study which compared two fractionation schedules in patients with low-risk prostate cancer, as well as the CHHiP trial which compared hypofractionated high-dose intensity-modulated radiotherapy schedules. They consider the optimal treatment schedules for salvage patients and touch upon the Early Prostate Cancer (EPC) trial with bicalutamide, noting their observations between the two trials. With regards to the STAMPEDE trial, they discuss and explore different rationales for the surprising overall survival advantage. This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).
Просмотров: 854 ecancer
Visiopharm: Connectivity Based Her2 IHC Membrane Image Analysis in Gastric Cancer
 
26:56
In 2009, Her 2 targeted therapy for gastric and gastro-oesophageal (G/GEJ) cancers became a reality for the first time with the presentation of the TOGA trial results at ASCO. Results of the TOGA trial placed a new focus on assessment of Her 2 status in these cancers. Although testing had been established for breast cancer there are significant differences between scoring of Her 2 immunohistochemistry between G/GEJ and breast cancers. There is significant heterogeneity in G/GEJ cancers and incomplete membrane staining is common and rarely seen in breast. For breast cancer, the HER2-CONNECT method has been CE-marked for in-vitro diagnostic use. This method provides a generalized (and continuous) measure of circumferential membrane staining across tumor cells. The aims of this study were to explore the feasibility of using the connectivity principle for gastric cancers, to define suitable cut-offs for analysis and assess whether we can reduce the number of 2+ cases without compromising patient outcomes. In a retrospective study of 44 cases from St. James’s Hospital Dublin the connectivity principle was found useful for determining HER2 status, based on the protein expression in gastric cancer patients. The cut-offs for determining negative versus positive HER2 status were found to be different (lower) reflecting the known difference in membrane morphology. Similar to findings for breast cancer, it was possible to reduce the number of 2+ cases by 77% without loss of accuracy (sensitivity/specificity) with respect to gene amplification. When excluding 2+ cases the concordance with manual reading is 100%.This study will now be taken forward as a prospective study. About our Speaker Dr. Stephen Finn is an academic Histopathologist with subspecialist interests limited to genitourinary pathology and cancer molecular diagnostics. He is a Prostate Cancer Foundation Young Investigator and co-director of the Cancer Molecular Diagnostic Laboratory at St James’s Hospital and Associate Professor of pathology at the University of Dublin, Trinity College. Dr. Finn qualified from University College, Cork (UCC) in 1998, completed his higher professional training in Dublin in 2005 and subsequently worked as staff pathologist and Senior Scientist at the Centre for Molecular Oncologic Pathology (CMOP) at the Dana Farber Cancer Institute in Boston, USA. He returned to Ireland in 2008 and worked as consultant pathologist at the Mid Western Regional Hospital Limerick before moving to his current position. He has PhD from Trinity College Dublin (2005) and is a Fellow of the Royal College of Pathologists, UK and a Fellow of the Faculty of Pathology of the Royal College of Physicians of Ireland. Dr. Finn is member of the steering Committee of the Transdisciplinary Prostate Cancer Partnership (ToPCaP). His specific research interests are related to image analysis in pathology, non-coding RNA signatures in aggressive prostate cancer and the role of the Circulating Tumor Cell in progression to metastasis.
Просмотров: 81 Visiopharm
Metastatic Tumor Coding - Primary vs. Secondary Cancer
 
03:44
Metastatic Tumor Coding - Defining Primary vs. Secondary Cancer http://www.cco.us/medical-coding-training-certification-products-yt Q: Can someone have a metastatic tumor without having a primary cancer? A: That’s goes back to the question, metastatic breast, that’s all they say in the documentation. So, what do we need to translate that is? How do we code that? The answer is “no.” A metastatic tumor is always caused by cancer cells from another part of the body. So, if you say “metastatic breast” then we know that that cancer came from someplace else, right? A metastatic tumor is always caused by cancer cells from another body part. It goes on to say, when that metastatic tumor is found first, the primary cancer can also be found, because they’ll look under the microscope and they’ll say, “This is breast tissue, breast cells, cancer cells in the bone,” so the primary site would be the breast and the secondary site would be the bone. Now, what if they haven’t determined from all of the tests what the primary is, but they know that the cells that are in the breast are not breast cells? They know it came from someplace else but they haven’t determined where. What do you do? So that’s a metastatic breast. They know because they looked at the cells, Pathology tells them it’s still a secondary cancer. READ MORE HERE: http://www.cco.us/metastatic-tumor-coding-cancer/ https://youtu.be/KSNiGUgb6hs ---------------------------------------- CLICK HERE: http://www.cco.us/medical-coding-training-certification-products-yt ---------------------------------------- More Information about metastatic tumor coding: Coding Neoplasms - health-information.advanceweb.com http://health-information.advanceweb.com/Web.../Coding-Neoplasms.aspx Jul 20, 2012 - If a patient is admitted with metastatic cancer, and the treatment is ... the secondary (metastatic) site, utilize the metastatic cancer code as the ... Coding Neoplasms Accurately http://health-information.advanceweb.com/.../Coding-Neoplasms-Accurately.as... Mar 2, 2004 - Metastasis results when the cancer cells migrate from their initial location to ... to ensure appropriate secondary or metastatic site coding. [PDF]Coding - BCBSGA https://www.bcbsga.com/.../pw_e2... Blue Cross and Blue Shield of Georgia “history” conundrum of cancer coding… Correctly Coding ... Correctly coding cancer diagnoses has long ... *Metastatic to a specified site = cancer has spread to. [PDF]Coding Neoplasms - American Health Information ... http://campus.ahima.org/audio/2007/RB041207.pdf Apr 12, 2007 - Information Management, including coding and data quality. Kathleen is ...... metastatic cancer, assign codes V58.69, Long-term. (current) use ... Tip: Coding for cancer - www.hcpro.com http://www.hcpro.com/HIM-246673-5707/Tip-Coding-for-cancer.html Feb 18, 2010 - A secondary site or “metastasis” is where the primary neoplasm has spread to another site. Carcinoma in situ is generally a non-invasive ... Squamous-cell carcinoma - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Squamous-cell_carcinoma Wikipedia Unlike basal-cell carcinomas, SCCs carry a significant risk of metastasis, often .... Papillary thyroid carcinoma (Code 8050/3); Verrucous squamous-cell ... Brain tumor - Wikipedia, the free encyclopedia https://en.wikipedia.org/wiki/Brain_tumor Wikipedia Secondary or metastatic brain tumors are more common than primary brain tumors, with about half of metastases coming from lung cancer. Primary brain tumors ... -------------------------------- CLICK HERE: http://www.cco.us/medical-coding-training-certification-products-yt ---------------------------------------- People who watched this video: https://youtu.be/KSNiGUgb6hs Also searched online for: Searches related to metastatic tumor coding metastatic brain tumor metastatic lung tumor metastatic bone tumor metastatic tumor spine metastatic tumor icd 9 metastatic tumor in neck metastatic tumor of the jaw diagnosis code for metastatic cancer ------------------------------------------- FOR MORE DETAILS: http://www.cco.us/medical-coding-training-certification-products-yt ------------------------------------------- CONNECT WITH US: http://www.facebook.com/cco.us http://www.youtube.com/medicalcodingcert http://www.youtube.com/codingcertification https://www.pinterest.com/codingcertorg/ https://plus.google.com/+CodingcertificationOrg https://www.linkedin.com/company/codingcertification-org ------------------------------------------ Don't forget to check out our YouTube Channel: https://www.youtube.com/user/MedicalCodingCert -------------------------------------------- #metastaticbraintumor #metastaticlungtumor #metastaticbonetumor #metastatictumorspine #metastatictumoricd9 #metastatictumorinneck #metastatictumorofthejaw #diagnosiscodeformetastaticcancer -------------------------------------------- VISIT OUR SITE: http://www.cco.us/cco-yt
Просмотров: 2347 MedicalCodingCert
Dr. George Morris, Chief Operations Officer of Valirx (VAL)
 
25:13
http://www.sharesmagazine.co.uk Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.
Просмотров: 752 Shares Magazine
Investigating colorectal cancer using epithelial organoid cultures
 
43:49
Presented By: Kai Kretzschmar, PhD - Postdoctoral researcher, Hubrecht Institute Speaker Biography: Kai Kretzschmar received his PhD from the University of Cambridge (UK) in 2014. During his doctoral training under the supervision of Fiona Watt, he studied the role of canonical Wnt signalling in the plasticity of adult murine skin and epidermal stem cell heterogeneity. Subsequently, Kai joined the laboratory of Hans Clevers at the Hubrecht Institute in Utrecht (The Netherlands) to investigate the heterogeneity of the tumour microenvironment in colorectal cancer. Webinar: Investigating colorectal cancer using epithelial organoid cultures Webinar Abstract: Colorectal cancer (CRC) develops during a multi-step process from small lesions of the intestinal epithelium. Genetic mutations in the canonical Wnt signalling pathway are considered to be the initial step of tumour formation. Using 3D organoid technology, tumour organoid cultures from CRC patients can be established. CRC organoids closely recapitulate key properties of the original tumour epithelium, including histological appearance, general gene and protein expression pattern and mutational load. Tumour organoids are amenable to radiation treatment, gene-drug association studies and high-throughput drug screens. Organoid cultures from adjacent healthy colon mucosa that retain the identity of the healthy intestinal epithelium in vitro can also be generated. Sequential introduction of the most commonly mutated CRC genes (APC, P53, KRAS and SMAD4) into healthy colon organoids using CRISPR/Cas9 genome editing technology allows for the modelling of tumorigenesis in vitro. Xenotransplantation of mutated organoids into mice recapitulates critical features of CRC progression and metastasis. In sum, (cancer) organoid technology can be used as experimental tool for basic research as well as diagnostic and therapeutic tool for (personalised) medicine. Learning Objectives: -Understand the advantages of epithelial organoids cultures for (colorectal) cancer modelling. -Learn about applications of (colorectal) cancer organoids for experimental, diagnostic and therapeutic use Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/investigating-colorectal-cancer-using-epithelial-organoid-cultures) 2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/investigating-colorectal-cancer-using-epithelial-organoid-cultures) 3. Click Here to get your PACE credits (Expiration date – February 22, 2020 09:00 AM): https://www.labroots.com/credit/pace-credits/2531/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 27 LabRoots
I SURVIVED THREE CANCERS TESTICULAR CARCINOID AND T CELL LYMPHOMA
 
02:38
HIT ON LINK http://www.carcinoidwade.com cancers lung cancer cancer treatment cancer treatments cancer therapy liver cancer pancreas cancer cancer hospital cancer symptoms prostate cancer cancer tumor cancer prostate cancer diagnosis cancer chemotherapy cancer about cancer beat cancer secondary cancer metastatic cancer cancer liver cancer news fighting cancer cancer help cancer center fight cancer prostata cancer ovarian cancer cancer cancer support cancer lung cancer pictures cancer images cancer control cancer photos cancer data cancer website cancer services beating cancer cancer ride cancer definition childrens cancer kids cancer cancer specialists cancer books cancer organisation cancer prognosis cancer stages cancer wiki cancer ward cancer facts cancer day cancer alternative type cancer world cancer day cancer diet alternative cancer treatments childrens cancer brain cancer cancer centers cancer clinical trials cancer cream cancer counselling leukemia cancer cancer causes cancer insurance its beautiful day for cancer cancer screening alternative cancer treatment cancer care skin cancer breast cancer cancer walk peritoneal cancer child cancer beautiful day for cancer jade goody cancer lobular cancer swayze cancer american cancer society alcohol cancer sarcoma cancer cancer specialist concrete cancer kids with cancer cancer today asparagus cancer asparagus and cancer asparagus for cancer cancer tattoo definition cancer metastases cancer cancer tattoos treatment cancer new cancer treatment treatment for cancer cancer food cancer grade prosate cancer cancer merchandise treatments for cancer I SURVIVED THREE CANCERS TESTICULAR CARCINOID AND T CELL LYMPHOMA
Просмотров: 1301 manofcancer
Deepak Kapoor, MD, Integrated Medical - Congressional Briefing - Prostate Cancer Screening
 
08:23
Deepak A. Kapoor, MD, Chairman and CEO, Integrated Medical Professionals Ana N. Fadich, Vice President, Men’s Health Network Congressional Briefing - Prostate Cancer Screening - Diagnostic Promises and USPSTF Challenges Congressional Men’s Health Caucus and Prostate Cancer Task Force - Congressmen Markwayne Mullin (OK) and Donald Payne, Jr. (NJ) (Co-Chairs) http://www.PCaAwareness.com http://www.ProstateHealthGuide.com http://www.ProstateCancerAwarenessMonth.com
Просмотров: 47 MHNMedia
Dr. Daniel Petrylak on Biomarker Discovery in Advanced Prostate Cancer
 
01:19
Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, discusses potential biomarkers currently being explored in castration-resistant prostate cancer (CRPC). For more resources and information regarding targeted therapies in cancer: http://targetedhc.com/
Просмотров: 80 Targeted Oncology
Support for Metastatic Prostate Cancer Patients
 
03:19
Metastatic, or advanced prostate cancer patients know they have no potential of being cured. Joel Nowak was diagnosed with this form of cancer twelve years ago. He is younger than most metastatic prostate cancer patients, which can make it difficult to find other men who can relate. There are support groups specifically for men with advanced stages of the disease, but can be hard to find. Malecare offers an online support group solely for men with metastatic prostate cancer. **** This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician. VIEW THE ARTICLE: http://www.prostatecancerlive.com/?p=12815 SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING PROSTATE CANCER NEWS http://www.youtube.com/subscription_c... VISIT PROSTATECANCERLIVE.com FOR TONS OF INFORMATIVE VIDEOS http://www.prostatecancerlive.com/# SUGGEST THE NEXT TOPIC FOR OUR PROSTATE CANCER EXPERTS! http://www.prostatecancerlive.com/# CONNECT WITH US! Google+: http://bit.ly/17F4WQr Facebook: https://www.facebook.com/pages/Prosta... Twitter: https://twitter.com/ProstateLive
Просмотров: 246 Prostate Cancer Live